CN112399969B - 硫酸氢氯吡格雷的ⅰ型晶体的制备方法 - Google Patents

硫酸氢氯吡格雷的ⅰ型晶体的制备方法 Download PDF

Info

Publication number
CN112399969B
CN112399969B CN201980046516.0A CN201980046516A CN112399969B CN 112399969 B CN112399969 B CN 112399969B CN 201980046516 A CN201980046516 A CN 201980046516A CN 112399969 B CN112399969 B CN 112399969B
Authority
CN
China
Prior art keywords
weight
clopidogrel
butanol
crystals
hydrogen sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980046516.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112399969A (zh
Inventor
武口俊太
中川贵洋乃
押元政臣
丸山美菜子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuki Gosei Kogyo Co Ltd
Original Assignee
Yuki Gosei Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuki Gosei Kogyo Co Ltd filed Critical Yuki Gosei Kogyo Co Ltd
Publication of CN112399969A publication Critical patent/CN112399969A/zh
Application granted granted Critical
Publication of CN112399969B publication Critical patent/CN112399969B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201980046516.0A 2018-07-12 2019-07-12 硫酸氢氯吡格雷的ⅰ型晶体的制备方法 Expired - Fee Related CN112399969B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-132101 2018-07-12
JP2018132101 2018-07-12
PCT/JP2019/027621 WO2020013305A1 (ja) 2018-07-12 2019-07-12 クロピドグレル硫酸塩のｉ型結晶の製造方法

Publications (2)

Publication Number Publication Date
CN112399969A CN112399969A (zh) 2021-02-23
CN112399969B true CN112399969B (zh) 2023-10-27

Family

ID=69143064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046516.0A Expired - Fee Related CN112399969B (zh) 2018-07-12 2019-07-12 硫酸氢氯吡格雷的ⅰ型晶体的制备方法

Country Status (3)

Country Link
JP (1) JP7323876B2 (https=)
CN (1) CN112399969B (https=)
WO (1) WO2020013305A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117447485A (zh) * 2023-10-23 2024-01-26 苏州正济药业有限公司 硫酸氢氯吡格雷的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620293A (zh) * 2001-12-18 2005-05-25 特瓦制药工业有限公司 氯吡格雷硫酸氢盐的多晶型
WO2011042804A2 (en) * 2009-10-08 2011-04-14 Jubliant Life Sciences Limited An improved process for the preparation of clopidogrel hydrogen sulfate form i

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
ITMI20022228A1 (it) * 2002-10-21 2004-04-22 Dinamite Dipharma S P A Sali di clopidogrel con acidi alchil-solforici.
PL382055A1 (pl) * 2007-03-23 2008-09-29 Koźluk Tomasz Nobilus Ent Sposób wytwarzania formy krystalicznej 1 wodorosiarczanu klopidogrelu

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620293A (zh) * 2001-12-18 2005-05-25 特瓦制药工业有限公司 氯吡格雷硫酸氢盐的多晶型
WO2011042804A2 (en) * 2009-10-08 2011-04-14 Jubliant Life Sciences Limited An improved process for the preparation of clopidogrel hydrogen sulfate form i

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Polymorph Control by Investigating the Effects of Solvent and Supersaturation on Clopidogrel Hydrogen Sulfate in Reactive Crystallization;Teng Zhang等;《Cryst. Growth Des.》;第第17卷卷;第6123-6131页 *

Also Published As

Publication number Publication date
CN112399969A (zh) 2021-02-23
WO2020013305A1 (ja) 2020-01-16
JP7323876B2 (ja) 2023-08-09
JPWO2020013305A1 (ja) 2021-07-15

Similar Documents

Publication Publication Date Title
JP6964595B2 (ja) リチウムビス（フルオロスルホニル）イミドの新規の製造方法
CN104736532B (zh) 改进的生产5‑(2,6‑二‑4‑吗啉‑4‑嘧啶)‑4‑三氟甲基吡啶‑2‑胺的方法
JP6995892B2 (ja) スガマデックスの製造方法
CN104418841B (zh) 一种光学纯雷贝拉唑及其钠盐的制备方法
KR100970434B1 (ko) 아데포비어 디피복실의 정제방법
CN107848981A (zh) 制备结晶n‑[2‑[[[1‑(4‑氯苯基)‑1h‑吡唑‑3‑基]氧基]甲基]苯基]‑n‑甲氧基氨基甲酸甲酯的新方法
CN110498770B (zh) 一种制备恶拉戈利中间体的方法
CN106146358B (zh) 一种合成氨基‑(n‑烷基)苯磺酰胺的方法
WO2014103811A1 (ja) 精製されたアミン化合物の製造方法
CN109496210A (zh) 贝利司他的多晶型及其制备方法
CN109689626B (zh) 合成近红外、闭链磺基-花青染料的方法
CN112399969B (zh) 硫酸氢氯吡格雷的ⅰ型晶体的制备方法
CN102241671B (zh) 前体相及其用于制备奥美拉唑对映体的四水合镁盐的用途
CN115836066A (zh) N-丁氧羰基-3-(4-咪唑-1-基甲基苯基)-5-异丁基噻吩-2-磺酰胺的合成方法
CN103880762B (zh) 一种1,2,3-三氮唑类化合物的制备方法
CN115716857A (zh) 一种石胆酸的精制方法
AU2006308660A1 (en) Process for the preparation of (omega -aminoalkylamino)alkyl halides and conversion to amifostine
BE1000128A3 (fr) Composants de catalyseurs pour catalyseurs de polymerisation d'alpha-olefines, et procede pour les fabriquer.
WO2020110831A1 (ja) チオラクトン誘導体の製造方法
CN103253688B (zh) 利用有机锡氟化物制备高纯度氟化锂以及六氟磷酸锂的方法
JP5305593B2 (ja) 高化学的ｒ−５−（２−（２−エトキシフェノキシエチルアミノ）プロピル）−２−メトキシベンゼンスルホンアミド塩酸塩の調製
CN106478751B (zh) 2′,3′-二-o-乙酰-5′-脱氧-5-氟-n4-[(戊氧基)羰基]胞嘧啶核苷的制备方法
US7750187B2 (en) Crystallization method for benzphetamine
CN104151396B (zh) 混合溶剂中催化合成s‑乙酰基‑l‑谷胱甘肽的方法
CN110785396A (zh) 3-羟基-3-甲基丁酸或其盐的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231027

CF01 Termination of patent right due to non-payment of annual fee